Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL (NCT04502394)
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
🩺 Plain-English Summary (8th-Grade Level)
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Who can join: Review the eligibility criteria below.
Location: Goshen Center for Cancer Care — Goshen, Indiana
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- Goshen Center for Cancer Care — Goshen, Indiana
- University of Cincinnati — Cincinnati, Ohio
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- UT Southwestern Medical Center — Dallas, Texas
- Royal Adelaide Hospital — Adelaide,
- Eastern Health - Box Hill Hospital — Box Hill,
- Barwon Health — Geelong,
- Royal Perth Hospital — Perth,
- Antwerp University Hospital (UZA) — Edegem,
- Jessa Ziekenhuis — Hasselt,
- University Hospital (UZ) Leuven — Leuven,
- Fakultni Nemocnice Hradec Kralove — Nový Hradec Králové,
- Fakultni nemocnice Ostrava — Ostrava,
- Vseobecna fakultni nemocnice v Praze — Prague,
- CHU de Nantes - Hôtel-Dieu — Nantes,
- Centre Henri Becquerel — Rouen,
- CHRU de Tours - Hôpital Bretonneau — Tours,
- Centro Riferimento Oncologico - Aviano — Aviano,
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola,
- ASST Grande Ospedale Metropolitano Niguarda — Milan,
- IRCCS Ospedale San Raffaele — Milan,
- Fondazione IRCCS Policlinico San Matteo — Pavia,
- Centro Ricerche Cliniche di Verona s.r.l. — Verona,
- Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii — Gdansk,
- Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii — Gdansk,
📞 Contact the Study Coordinator
Phone: (650) 542-0136
Email: jmei@kartosthera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B Cell Lymphoma
- Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia — Honolulu, Hawaii
- Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma — Boston, Massachusetts
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients — Morristown, New Jersey
- Copanlisib Plus Venetoclax in R/R DLBCL — Duarte, California
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers — Basking Ridge, New Jersey
- Split-Dose R-CHOP for Older Adults With DLBCL — Madison, Wisconsin
Explore by condition: All Diffuse Large B Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.